Discovering ZNRD2-DT: A Potential Drug Target and Biomarker (G254100)

Target Name: ZNRD2-DT

NCBI ID: G254100

ZNRD2-DT

Other Name(s): ZNRD2-AS1 | ZNRD2 divergent transcript | SSSCA1-AS1

Discovering ZNRD2-DT: A Potential Drug Target and Biomarker

ZNRD2-DT (ZNRD2-AS1), a protein encoded by the ZNRD2 gene, is a potential drug target and biomarker associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNRD2-DT has been identified as a promising target for drug development due to its unique structure, localization, and biology.

The ZNRD2 gene is located on chromosome 12q34, and it encodes a protein that is expressed in various tissues and organs, including brain, spinal cord, muscle, heart, and gut. ZNRD2-DT is a 21-kDa protein that consists of 194 amino acids acid residues. It has a unique topology, with a C-terminal region that is rich in conservation and a N-terminal region that is known for its ability to interact with various molecules, including drug targets.

ZNRD2-DT has been shown to play a critical role in several biological processes, including cell adhesion, migration, and invasion. It is a member of the ZNF2 family, which is known for its role in regulating gene expression and cell behavior. DT has been shown to interact with several key transcription factors, including NF-kappa-B, AP-1, and STAT3.

In addition to its role in cell biology, ZNRD2-DT has also been linked to several diseases. Its expression has been observed in various types of cancer, including breast, ovarian, and colorectal cancer. It has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. ZNRD2-DT has also been implicated in autoimmune disorders, such as rheumatoid arthritis and type 1 diabetes.

The potential drug targets for ZNRD2-DT are vast and varied. Its unique structure and biology make it an attractive target for small molecules, antibodies, and other therapeutic agents. Some potential drug targets include:

1. Cancer: ZNRD2-DT has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. Targeting ZNRD2-DT may be a promising strategy for the development of new cancer therapies.
2. Neurodegenerative diseases: ZNRD2-DT has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Targeting ZNRD2-DT may be a promising strategy for the development of new therapies for these conditions.
3. Autoimmune disorders: ZNRD2-DT has been implicated in the development and progression of several autoimmune disorders, including rheumatoid arthritis and type 1 diabetes. Targeting ZNRD2-DT may be a promising strategy for the development of new therapies for these conditions.

In conclusion, ZNRD2-DT is a protein that has potential as a drug target and biomarker. Its unique structure and biology make it an attractive target for small molecules, antibodies, and other therapeutic agents. Further research is needed to fully understand the role of ZNRD2-DT in biology and disease, and to develop effective therapies based on its unique properties.

Protein Name: ZNRD2 Divergent Transcript

The "ZNRD2-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNRD2-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets